Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

This study has been terminated.
(Due to potential concerns about liver safety (See Detailed Description))
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01829464
First received: April 9, 2013
Last updated: January 23, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to evaluate the effect of TAK-875 (fasiglifam) in combination with sitagliptin on glycemic control in adults with type 2 diabetes.


Condition Intervention Phase
Diabetes
Drug: Placebo
Drug: TAK-875
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The change from Baseline to Week 24 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).


Secondary Outcome Measures:
  • Percentage of participants with HbA1c <7% at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

  • Change from baseline in fasting plasma glucose at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The change between the fasting plasma glucose value collected at week 24 relative to baseline.


Enrollment: 90
Study Start Date: May 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
Drug: Placebo
TAK-875 placebo-matching tablets
Experimental: TAK-875 25 mg
TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
Drug: TAK-875
TAK-875 tablets
Experimental: TAK-875 50 mg
TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
Drug: TAK-875
TAK-875 tablets

Detailed Description:

The drug being tested in this study is called TAK-875 (fasiglifam). Fasiglifam is being tested to treat people who have type 2 diabetes mellitus and are currently taking sitagliptin (with or without metformin). This study will evaluate glycemic control in people who take fasiglifam plus sitagliptin compared with placebo plus sitagliptin.

The study will enroll approximately 390 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need; all participants will be on 100 mg sitagliptin and may or may not be on metformin background treatment):

  • fasiglifam 25 mg
  • fasiglifam 50 mg
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient All participants will be asked to take one tablet at the same time each day throughout the study.

This multi-centre trial will be conducted in North America and Latin America. The overall time to participate in this study is approximately 38 weeks. Participants will make 15 visits to the clinic.

Due to potential concerns about liver safety, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks.

For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant is male or female and aged 18 years or older with a historical diagnosis of T2DM.
  4. The participant meets one of the following criteria:

    • The participant has an HbA1c between 7.5% and 10.5%, inclusive and has been taking a stable dose of sitagliptin 100 mg for at least 8 weeks, with or without metformin, prior to the Screening Visit. A participant who is taking metformin must have received a stable daily dose (≥1500 mg or documented maximum tolerated dose [MTD]) for at least 8 weeks before Screening. This participant will enter the 2-week single-blind Placebo Run-In Period according to Study Schedule A, or;
    • The participant has an HbA1c between 7.5% and 10.5%, inclusive and has been taking any other DPP-IV inhibitor (with or without metformin) for at least 8 weeks prior to the Screening Visit. A participant who is taking metformin must have received a stable daily dose (≥1500 mg or documented MTD) for at least 8 weeks before Screening. This participant will enter the 8-week Switching Period according to Study Schedule B. Following this 8-week period, the participant must qualify for all Inclusion/Exclusion Criteria prior to entering the 2-Week Placebo Run-in Period by completing the Week ( 3) procedures including having an HbA1c level between 7.5% and 10.5%.

    Note: An enrollment cap may be applied to ensure no more than approximately 20% of randomized participants are receiving a DPP-IV inhibitor without metformin at baseline.

  5. The participant has had no treatment with antidiabetic agents other than DPP-IV inhibitors and metformin within 2 months prior to Screening (Exception: if a participant has received other antidiabetic therapy for ≤7 consecutive days within the 2 months prior to Screening).
  6. The participant has a body mass index (BMI) ≤45 kg/m2 at Screening.
  7. Participants regularly using other, non-excluded medications must be on a stable dose for at least 4 weeks prior to screening. However, PRN (as needed) use of prescription or over-the-counter medication is allowed at the discretion of the investigator.
  8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from signing of the informed consent throughout the duration of the study and for 30 days after the last dose of study drug.
  9. The participant is able and willing to monitor glucose with a home glucose monitor and consistently record his or her own blood glucose concentrations and complete participant diaries.

Exclusion Criteria:

  1. Has received any investigational compound within 30 days prior to Screening or has received an investigational antidiabetic drug within 3 months prior to Screening.
  2. Has been randomized into a previous TAK-875 study.
  3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, or sibling; biological or legally adopted) or may consent under duress.
  4. Donated or received any blood products within 12 weeks prior to Screening or is planning to donate blood during the study.
  5. Has a hemoglobin ≤12 g/dL (≤120 gm/L) for males and ≤10 g/dL (≤100 gm/L) for females at the Screening Visit.
  6. Has a systolic blood pressure ≥160 mm Hg or diastolic pressure ≥95 mm Hg at Screening (If the participant meets this exclusion criteria, the assessment may be repeated once at least 30 minutes after the initial measurement and a decision will be made based on the second measurement).
  7. Has history of cancer that has been in remission for <5 years prior to Screening. (Exception: A history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed.)
  8. Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >2.0x the upper limit of normal (ULN) at Screening.
  9. Has a total bilirubin level greater than the ULN at Screening. Exception: if a participant has documented Gilbert's Syndrome, they will be allowed with an elevated bilirubin level per the investigator's discretion.
  10. Has a serum creatinine ≥1.5 mg/dL (≥133 μmol/L) [males] and ≥1.4 mg/dL (≥124 μmol/L) [females] and/or estimated glomerular filtration rate (GFR) <60 mL/min/1.73m^2 at Screening.
  11. Has uncontrolled thyroid disease.
  12. Has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
  13. Has had gastric banding or gastric bypass surgery within one year prior to Screening.
  14. Has a known history of infection with human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  15. Had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 3 months prior to or at Screening.
  16. Has a history of pancreatitis.
  17. Has a history of hypersensitivity, allergies or has had an anaphylactic reaction(s) to any component of TAK-875 as well as sitagliptin.
  18. Has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse within 2 years prior to Screening.
  19. Received excluded medications prior to the Screening Visit or is expected to receive excluded medications.
  20. If female, is pregnant (confirmed by laboratory testing, ie, serum/urine human chorionic gonadotropin (hCG), in females of childbearing potential) or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  21. Is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent is available.
  22. Has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01829464

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
Dothan, Alabama, United States
Muscle Shoals, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, California
Anaheim, California, United States
El Cajon, California, United States
Long Beach, California, United States
Modesto, California, United States
North Hollywood, California, United States
Norwalk, California, United States
Pismo Beach, California, United States
San Diego, California, United States
Vista, California, United States
West Hills, California, United States
United States, Florida
Boca Raton, Florida, United States
Boynton Beach, Florida, United States
Bradenton, Florida, United States
Clearwater, Florida, United States
Cocoa, Florida, United States
Doral, Florida, United States
Miami, Florida, United States
North Miami, Florida, United States
Pembroke Pines, Florida, United States
Port Orange, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Savannah, Georgia, United States
Woodstock, Georgia, United States
United States, Idaho
Boise, Idaho, United States
Meridian, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
Apex Medical Research, MI, Inc
Chicago, Illinois, United States, 60616
United States, Indiana
Avon, Indiana, United States
Greenfield, Indiana, United States
Muncie, Indiana, United States
United States, Iowa
Council Bluffs, Iowa, United States
United States, Kansas
Topeka, Kansas, United States
United States, Kentucky
Owensboro, Kentucky, United States
United States, Maryland
Oxon Hill, Maryland, United States
United States, Massachusetts
Fall River, Massachusetts, United States
United States, Missouri
St. Louis, Missouri, United States
Washington, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Hampshire
Nashua, New Hampshire, United States
United States, New Jersey
Elizabeth, New Jersey, United States
Haddon Heights, New Jersey, United States
United States, New York
Albany, New York, United States
Rosedale, New York, United States
United States, North Carolina
Calabash, North Carolina, United States
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Morganton, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Dayton, Ohio, United States
Maumee, Ohio, United States
United States, Oklahoma
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Feasterville, Pennsylvania, United States
Harleysville, Pennsylvania, United States
Levittown, Pennsylvania, United States
Uniontown, Pennsylvania, United States
United States, South Carolina
Fort Mill, South Carolina, United States
Greer, South Carolina, United States
Spartanburg, South Carolina, United States
United States, Tennessee
Crossville, Tennessee, United States
Knoxville, Tennessee, United States
United States, Texas
Carrollton, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Irving, Texas, United States
Katy, Texas, United States
Lewisville, Texas, United States
McKinney, Texas, United States
New Braunfels, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
Tomball, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Burke, Virginia, United States
Manassas, Virginia, United States
Argentina
Rosario, Santa Fe, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Salta, Argentina
Peru
Lima, Peru
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director, MD Takeda
  More Information

No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01829464     History of Changes
Other Study ID Numbers: TAK-875_303, U1111-1124-2270
Study First Received: April 9, 2013
Last Updated: January 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Sitagliptin
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Incretins
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors

ClinicalTrials.gov processed this record on November 20, 2014